Needham downgrades Biogen on slow growth of Alzheimer's drug

Investing.comNov 18, 2024 4:52 PM

View all comments（0）



Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

The brokerage stated that Leqembi’s sales trajectory will continue to see a gradual increase, rather than a sharp uptick, and as a result, it has lowered its 2025 and 2026 revenue estimates for the drug by 16% and 30%, respectively, compared to prior consensus expectations.

Needham also highlighted that other key Biogen products, such as Skyclarys and Zurzuvae, are expected to ramp up slowly, but may not be sufficient to offset declines in the company's base business in the near term.

Needham pointed out that business development deals could act as a catalyst for the stock, although the timing and nature of such deals remain uncertain.

Additionally, the brokerage noted that upcoming Phase 3 data for Litifilimab, a lupus treatment drug, could boost the stock by mid-single digits if the results are positive.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

US Pre-Market: Memory Chip Stocks Rebound, IBM Plunges 22%, CPI and Warsh Hearing Arrive Together

TradingKey - On July 14, Eastern Time, the three major US stock index futures showed mixed performance in pre-market trading. As of press time, Nasdaq 100 Index futures rose 0.49%, S&P 500 Index futures edged down 0.12%, and Dow Jones Industrial Average futures fell 0.69%.

Intel Enters Space Computing Market for the First Time, Releases 18A Space-Grade Chip Starfire

TradingKey - Intel (INTC) recently unveiled a space-grade System-on-Chip (SoC) code-named Starfire, marking the company’s official entry into the space computing market with its first self-developed dedicated chip. The product is primarily designed for satellites, spacecraft, and other equipment in extreme environments, focusing on meeting the demands of commercial aerospace, defense, and government customers for low power consumption, high reliability, and artificial intelligence computing capabilities.

Kospi Index Slumps 30%: Breaches 7,000-Point Technical Level, Has South Korea Stock Market Officially Entered Bear Market?

Over the past month, the KOSPI Index has recorded a cumulative plunge of approximately 30% and is losing the key support level of 7,000 points. Having broken its bullish technical structure, the index may continue to decline toward the 5,000-point mark in the second half of the year.

AMD (AMD) Stock Price Forecast: Zen 6 Venice Launches July 22, Helios vs Nvidia Vera Rubin; Is $584 Next?

TradingKey - AMD launches Zen 6 Venice on July 22 at Advancing AI 2026. Citi says expect industry-shaking announcements. Stifel raised to $635. Helios rack-scale is Meta’s Nvidia alternative. At $539, the $557.70 trigger is the week-ahead watch level.

US June CPI Preview: Can Cooling Inflation Open Up Fed Rate Cut Expectations? How Will US Stocks, the Dollar, and Gold React?

TradingKey - The United States will release June Consumer Price Index (CPI) data this Tuesday, marking one of the most critical macro events for global financial markets this week. Following a significant pickup in U.S. inflation in May, and as recent Middle East tensions, oil price volatility, Fed meeting minutes, and non-farm payroll data collectively shift market expectations, the June CPI will significantly impact the Federal Reserve's next policy assessment while directly determining the short-term trajectory of U.S. stocks, the U.S. Dollar (USD), and Gold (XAUUSD).

Featured Tools